Objectives: To evaluate the clinical impact of cachexia, defined by the combination of albumin and C-reactive protein levels, in patients with unresectable locally advanced head and neck squamous cell carcinomas who received chemoradiotherapy in a phase II trial of JCOG0706. Methods: Forty-five patients received radiation for a total of 70 Gy/35fr concurrently with S-1 and cisplatin. The present analysis was conducted in 44 patients with available data. The association between treatment efficacy and cachexia was investigated. Pretreatment cachexia was defined as a serum albumin level of less than 3.5 mg/dl and C-reactive protein level of more than 0.5 mg/dl. Results: Among the 44 patients, 5 patients had cachexia. On comparison with the cachexic and non-cachexic patients, the percentage of clinical complete remission (20% vs 72%), time to treatment failure at 3 years, (20% vs 53%) and proportion of treatment completion (20% vs 79%) were statistically worse in the cachexic patients, while overall survival, progression-free survival and local progression-free survival at 3 years tended to be worse in cachexic patients. Conclusions: This supplementary analysis from a prospective study suggests that a pretreatment status of cancer cachexia is a prognostic factor for treatment outcomes and compliance in patients © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 37 with locally advanced head and neck squamous cell carcinomas treated with chemoradiotherapy, and a candidate stratification factor in future prospective trials in this population.
Introduction
In the management of cancer, cachexia is considered to be an independent prognostic factor. Most patients with advanced stage cancer experience cancer-induced cachexia, a complex metabolic syndrome associated with an underlying illness which is characterized by loss of muscle with or without loss of fat mass (1) . Cachexia results from an alteration in metabolic state due to tumor-derived factors, loss of anabolic stimuli and an increase in catabolic processes. Cachexia is caused by the carrying and expression of genes for various cytokines, including tumor necrosis factor, interleukin (IL)-6 and interferon-gamma (2) . Among these, IL-6 causally affects the body in cancer patients by inducing protein catabolism, lipolysis, insulin resistance and appetite suppression (3) . Of note, cytokines such as IL-6 and tumor necrosis factor upregulate the expression of Creactive protein (CRP), an essential acute phase reactant synthesized in hepatocytes that acts as a surveillance molecule for activation of the adaptive immune system. Preoperative CRP level is correlated with the tissue concentration of IL-6 in tumors and its elevation predicts recurrent disease and a shorter survival time (4) . The Glasgow Prognostic Score (GPS), proposed in 2004, evaluates cachexia using a combination of albumin and CRP level. Several studies have shown that CRP is useful as an immune-nutritional predictor of post-operative mortality for various sites of cancer (5-9), including two retrospective studies of head and neck squamous cell carcinoma (10, 11) . To date, however, no study has analyzed the association between the pretreatment status of cancer cachexia and prognosis in locally advanced head and neck squamous cell carcinomas (LAHNSCC) using prospectively collected data.
The Japan Clinical Oncology Group (JCOG) conducted JCOG0706 (UMIN000001272), a multi-institutional phase II study, to evaluate the safety and efficacy of concurrent chemoradiotherapy (CRT) with S-1 plus cisplatin (CDDP) in patients with unresectable LAHNSCC. According to the eligibility criteria for this prospective study, patients with a bad performance status (PS) were not enrolled and patient background was uniform. A total of 45 patients from 13 institutions were enrolled under the approval of the respective institutional review board (12, 13) .
Here, using data prospectively collected in JCOG0706, we conducted a supplementary study (JCOG0706-S2) to elucidate the clinical impact of pretreatment cachexia in patients with unresectable LAHNSCC who were treated with CRT.
Patients and methods
We analyzed the association between treatment outcomes and cachexia, as defined by a modified definition of GPS (14) among patients with unresectable LAHNSCC who were enrolled in JCOG0706.
For inclusion in JCOG0706, patients fulfilled all of the following criteria: histologically diagnosed squamous cell carcinoma; primary lesion located at the oropharynx, hypopharynx or larynx; unresectable LAHNSCC that fulfilled at least one of the following conditions: (i) primary lesion or cervical lymph node metastasis invasion to carotid artery, cranial base or cervical vertebrae; (ii) cervical lymph node metastasis of N2c or N3 (UICC/TNM, sixth edition); or (iii) T4 primary lesion located at the oropharynx; no fistula due to primary lesion or cervical lymph node metastasis; no distant metastasis; age between 20 and 75 years; PS between 0 and 1 according to the criteria proposed by the Eastern Cooperative Oncology Group (ECOG) in the USA; no prior radical surgery for head and neck cancer; no prior treatment for any other malignancies with chemotherapy, radiation therapy or endocrine therapy; sufficient organ function, including white blood cell count from 4000 to 12 000/mm 3 ; normal electrocardiogram; and written informed consent. Chemotherapy consisted of S-1 twice daily on days 1-14 at 60 mg/m 2 /day and cisplatin at 20 mg/m 2 /day on days 8-11, repeated twice at a 5-week interval. The rationale for the divided doses of CDDP was described in our previous phase I study (10) . Single daily radiation of 2 Gy in 35 fractions for a total of 70 Gy was given concurrently starting on day 1. For patients achieving an objective response after CRT, two additional cycles of chemotherapy were administered ( Fig. 1 ). The details of concurrent CRT, adjuvant chemotherapy, salvage surgery if applicable, detailed treatment evaluation and dose modification are described in our previous paper (11, 15) . The primary endpoint of JCOG0706 was the percentage of clinical complete remission (CCR), namely, the proportion of complete response (CR) and good partial response (PR) in all eligible patients. Good PR is characterized as a secondary change unique to post CRT that is regarded as a remaining scar but not residual tumor. Good PR in this study was defined as lesions ≤10 mm in size or not enhanced on contrasted computed tomography scan. The secondary endpoints were overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS), time to treatment failure (TTF), and the proportion of treatment completion. OS was defined as days from enrollment to death from any cause. PFS was defined as the time from enrollment to any disease progression or death from any cause. LPFS was defined as the time from enrollment to locoregional disease progression or death from any cause. TTF was defined as the time from enrollment to any disease progression, off-protocol treatment or death from any cause. Survival curves were estimated by the Kaplan-Meier method and compared by the two-sided log-rank test. Hazard ratios for time-to-event endpoints were estimated by the Cox proportional hazard model. CCR and proportion of treatment completion between the arms were compared with Fisher's exact test. All analyses were carried out using SAS 9.4 (SAS Institute, Cary, NC, USA).
We investigated the relationship between treatment efficacy and pretreatment cachexia using the modified GPS definitions of cachexia. Pretreatment cachexia was defined as a serum CRP level of more than 0.5 mg/dl (14) , which is the cut-off value reported as a prognostic factor for Japanese patients with stage I and II colorectal cancer. Although cachexia is more generally defined by a serum CRP level of more than 1.0 mg/dl, for example in the GPS (16, 17) and modified GPS (18), our present 0.5 mg/dl value was established following the widespread adoption in Japan of highly accurate CRP measuring systems having a lower limit value of 0.3 mg/dl (14) .
Results
From July 2008 to July 2010, 45 patients were registered in JCOG0706. Of these, this present supplementary analysis included 44 whose serum albumin and CRP levels before the protocol treatment were available. Patient characteristics are listed in Table 1 . Forty-two patients were male and two were female, median age was 63 years old, and PS included 0 (n = 35) and 1 (n = 9). Cancer stages were IVA (n = 29) and IVB (n = 15). The most common primary site was the oropharynx (57%, 25/44). All but one patient had either a primary site with T3 or T4 or neck lymph node with N2b or worse. Thirty-five patients underwent prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement. Before the start of CRT, eight patients required feeding tubes for nutritional support, namely, a PEG feeding tube in seven and a nasal tube in one.
Among 44 eligible patients, 32 patients completed two cycles of chemotherapy concurrently with RT and two cycles of adjuvant chemotherapy. The proportion of treatment completion was 73%; after the completion of two cycles of adjuvant chemotherapy, 28 patients achieved CR or good PR, while 4 patients who did not achieve CR or good PR received protocol salvage surgery. During the protocol therapy, eight patients discontinued treatment due to adverse events, two patients declined further treatment due to adverse events and two patients were determined to be incurable.
CCR was 66% (29/44). After a median follow-up of 3.5 years for all enrolled patients, 3-year LPFS was 63.6% (95% CI 47.7-75.9), with a 3-year PFS of 61.4% (95% CI 45.4-73.9), a 3-year OS of 65.9% (95% CI 50.0-77.7) and a 3-year TTF of 50.0% (95% CI 34.6-63.6).
Comparison of treatment outcomes between cachexic and noncachexic patients: five patients were identified as cachexic, with a PS of 0 (n = 2) or 1 (n = 3), and 39 as non-cachexic, with a PS of 0 (n = 33) or 1 (n = 6). Before starting CRT, two cachexic patients required feeding tubes for nutritional support (PEG tube, 1; nasal tube, 1). Three cachexic patients underwent prophylactic PEG tube placement. Among the five cachexic patients, the proportion of treatment completion was 20%; one patient achieved good PR, three patients discontinued due to severe adverse events and one patient was determined to be incurable.
Among the 39 non-cachexic patients, the proportion of treatment completion was 79%; 27 patients achieved CR or good PR, four patients who did not achieve CR or good PR received protocol salvage surgery, three patients were discontinued due to severe adverse events, two patients declined to continue due to adverse events and one patient was determined to be incurable. The proportion of treatment discontinuation due to adverse events and patient refusal related to adverse events in the non-cachexic group (7/39, 18%) tended to be lower than that in the cachexic group (3/5, 60%, P = 0.502).
CCR in the cachexic and non-cachexic patients was 20% (1/5) and 72% (28/39), respectively (P = 0.039). TTF at 3 years was 20.0% (95% CI 47.7-75.9) in the cachexic patients vs. 53.8% (95% CI 37.2-67.9) (P = 0.0047) in the non-cachexic group. The proportion of treatment completion in the cachexic and noncachexic groups was 20% (1/5) and 79% (31/39), respectively (P = 0.015). OS, PFS and LPFS tended to be lower in the cachexic group.
As summarized in Table 2 , all treatment outcomes tended to be worse in the cachexic patients.
Discussion
In this supplementary analysis of JCOG0706, we evaluated the clinical impact of cachexia in LAHNSCC patients treated with CRT. Results showed that around 10% of patients were cachexic, but like the non-cachexic patients were in a good general condition, with a PS 0 or 1. TTF and TCR were statistically worse in the cachexic than non-cachexic patients, and most treatment outcomes tended to be worse. These results suggest that a pretreatment status of cancer cachexia might be prognostic for treatment outcome. They also suggest that a pretreatment status of cancer cachexia should be considered as a stratification factor in future randomized trials in LAHNSCC.
Although many cytokines are involved in cachexia, circulating IL-6 levels can be clearly described as either elevated or a predictor of weight loss in human cancer cachexia (19, 20) . IL-6 is the main cytokine involved in induction of the acute phase response, which includes the synthesis of certain proteins in the liver, such as CRP. Upregulation of the IL-1-IL-6 network stimulates systemic expression of CRP (4, 21) . GPS is an inflammation-based score which is derived as follows: patients with both elevated CRP (>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl) are assigned a score of 2; those with only one of these biochemical abnormalities are assigned a score of 1; and those with neither abnormality are assigned a score of 0 (16) . A previous study concluded that the prognostic value of GPS for survival was independent of cancer staging system (17) . As the proportion of patients in that study with a GPS of 1 due to hypoalbuminemia without CRP elevation was low and OS was not substantially worse than that of patients with a GPS of 0, a modified GPS was developed in which these patients were assigned a score of 0 (18) . Pretreatment evaluation using this immune-nutritional indicator might detect cachexia at an earlier phase when it might possibly be reversible in combination with supportive intervention.
This study has several limitations. First, this supplementary analysis was conducted using the available data of 44 patients in the relatively small JCOG0706 phase II study (N = 45). In addition, there were only five cachexic patients in this cohort. Thus, we only performed univariate analysis because multivariate analysis is not applicable to this population. Second, we cannot exclude the possibility that silent or minor aspiration due to dysphagia from the primary disease might have affected the elevation of CRP levels and decrease in albumin. Because we enrolled patients who met the eligibility criteria of an ECOG-PS of 0/1 and a white blood cell count below 12 000/mm 3 , we were at least able to exclude patients with active infections and those in poor general condition. Finally, because this supplementary analysis was not prospectively planned and conducted using a finalized database, no nutritional cytokines or biomarkers were available. Accordingly, a prospective immunenutritional trial with the measurement of nutritional cytokines and biomarkers should be considered. Further, the development of immune-nutritional supportive treatment to improve cachexia may improve the outcome of anticancer therapy in these patients.
Conclusions
This supplementary analysis from a prospective study of JCOG0706 suggests that a pretreatment status of cancer cachexia is a prognostic factor for treatment outcomes and compliance in patients with LAHNSCC treated with CRT. Further, pretreatment cachexia appears to be a candidate stratification factor for future prospective trials in this population. 
